Share This Article:

Iron-Restricted Erythropoiesis in a Population of Elderly Hospitalized Anemic Patients

Abstract Full-Text HTML Download Download as PDF (Size:169KB) PP. 30-33
DOI: 10.4236/ojbd.2012.22006    3,136 Downloads   6,287 Views   Citations

ABSTRACT

The aim of this observational study was to assess the prevalence of iron-restricted erythropoiesis (IRE) in a population of elderly hospitalized anemic patients. Prevalence of IRE was found to be 41% and the most common clinical diagnoses in such patients were hematologic malignancies and solid tumors. Comparison between patients with IRE and non-IRE patients revealed that mean corpuscular volume, mean corpuscular hemoglobin, iron, and transferrin saturation were significantly lower in the IRE group, whereas no significant difference was found for Hb, transferrin, or ferritin. There was a more pronounced inflammatory response in the IRE group demonstrated by a higher C-reactive protein level.

Conflicts of Interest

The authors declare no conflicts of interest.

Cite this paper

T. Karlsson, "Iron-Restricted Erythropoiesis in a Population of Elderly Hospitalized Anemic Patients," Open Journal of Blood Diseases, Vol. 2 No. 2, 2012, pp. 30-33. doi: 10.4236/ojbd.2012.22006.

References

[1] L. Goodnough, E. Nemeth and T. Ganz, “Detection, Evaluation, and Management of Iron-Restricted Erythropoiesis,” Blood, Vol. 116, No. 23, 2010, pp. 4754-4761. doi:10.1182/blood-2010-05-286260
[2] D. Henry, “Supplemental Iron: A Key to Optimizing the Response of Cancer-Related Anemia to rHuEPO?” The Oncologist, Vol. 3, No. 4, 1998, pp. 275-278.
[3] C. Roy and N. Andrews, “Anemia of Inflammation: The Hepcidin Link,” Current Opinion in Hematology, Vol. 12, No. 2, 2005, pp. 107-111. doi:10.1097/00062752-200503000-00001
[4] E. Nemeth and T. Ganz, “Hepcidin and Iron-Loading Anemias,” Haematologica, Vol. 91, No. 6, 2006, pp. 727732.
[5] E. Nemeth, S. Rivera, V. Gabayan, C. Keller, S. Taudorf, K. Pedersen and T. Ganz, “IL-6 Mediates Hypoferremia of Inflammation by Inducing the Synthesis of the Iron Regulatory Hormone Hepcidin,” Journal of Clinical Investigation, Vol. 113, No. 9, 2004, pp. 1271-1276.
[6] E. Nemeth, M. Tuttle, J. Powelson, M. Vaughn, A. Donovan, D. McVey Ward, T. Ganz and J. Kaplan, “Hepcidin Regulates Cellular Iron Efflux by Binding to Ferroportin and Inducing Its Internalization,” Science, Vol. 306, No. 5704, 2004, pp. 2090-2093. doi:10.1126/science.1104742
[7] S. Rivera, L. Liu, E. Nemeth, V. Gabayan, O. Sorensen and T. Ganz, “Hepcidin Excess Induces the Sequestration of Iron and Exacerbates Tumor-Associated Anemia,” Blood, Vol. 105, No. 4, 2005, pp. 1797-1802. doi:10.1182/blood-2004-08-3375
[8] L. Viatte, G. Nicolas, D-Q. Lou, M. Bennoun, J.-C. Lebordes Brion, F. Cannone Hergaux, K. Sch?nig, H. Bujard, A. Kahn, N. Andrews and S. Vaulont, “Chronic Hepcidin Induction Causes Hypoferremia and Alters the Pattern of Cellular Iron Accumulation in Hemochromatotic Mice,” Blood, Vol. 107, No. 7, 2006, pp. 2952-2958. doi:10.1182/blood-2005-10-4071
[9] D. Weinstein, C. Roy, M. Fleming, M. Loda, J. Wolfsdorf and N. Andrews, “Inappropriate Expression of Hepcidin Is Associated with Iron Refractory Anemia: Implications for the Anemia of Chronic Disease,” Blood, Vol. 100, No. 10, 2002, pp. 3776-3781. doi:10.1182/blood-2002-04-1260
[10] F. Locatelli, A. Covic, K-U. Eckardt, A. Wiecek, R. Wanholder and on Behalf of the ERA-EDTA Advisory Board, “Anemia Management in Patients with Chronic Kidney Disease: A Position Statement by the Anemia Working Group of European Renal Best Practice,” Nephrology Dialysis Transplantation, Vol. 24, No. 2, 2009, pp. 348-354. doi:10.1093/ndt/gfn653
[11] T. Karlsson, “Effects of Iron Supplementation on Erythropoietic Response in Patients with Cancer-Associated Anemia Treated by Means of Erythropoietic Stimulating Agents,” International Scholarly Research Network Hematology, Vol. 2011, No. 2011, 2011, Article ID 108397, 6 p. http://hindawi.com/journals/ane/2011/925907
[12] G. Weiss, “Iron and Immunity: A Double Egged Sword,” European Journal of Clinical Investigation, Vol. 32, Suppl. 1, 2002, pp. 70-78. doi:10.1046/j.1365-2362.2002.0320s1070.x
[13] A. Erslev, “Anemia of Chronic Disease,” In: E. Beutler, M. Lichtmann, B. Coller, T. Kipps and U. Seligsohn, Eds., Williams Hematology, 6th Edition, McGraw-Hill, New York, 2001, pp. 481-487.
[14] K. Punnonen, K. Irjala and A. Rajam?ki, “Iron-Deficiency Anemia Is Associated with High Concentrations of Transferrin Receptor in Serum,” Clinical Chemistry, Vol. 40, No. 5, 1994, pp. 774-776.
[15] K. Punnonen, K. Irjala andA. Rajam?ki,“Serum Transferrin Receptor and Its Ratio to Serum Ferritin in the Diagnosis of Iron Deficiency,” Blood, Vol. 89, No. 3, 1997, pp. 1052-1057.
[16] G. Weiss and L. Goodnough, “Anemia of Chronic Disease,” New England Journal of Medicine, Vol. 352, No. 10, 2005, pp.1011-1023. doi:10.1056/NEJMra041809
[17] C. Thomas and L. Thomas, “Anemia of Chronic Disease: Pathophysiology and Laboratory Diagnosis,” Laboratory Hematology, Vol. 11, No. 1, 2005, pp. 14-23. doi:10.1532/LH96.04049
[18] D. Henry, N. Dahl and on Behalf of the Ferrleict Cancer Study Group, “Iron or Vitamin B12 Deficiency in Anemic Patients Prior to Erythropoiesis-Stimulating Agent Therapy,” Community Oncology, Vol. 4, No. 2, 2007, pp. 95-101. doi:10.1016/S1548-5315(11)70057-2
[19] M. Basora, R. Delofeu, F. Salazar, L. Quinto and C. Gomar, “Improved Preoperative Iron Status Assessment by Soluble Transferrin Receptor in Elderly Patients Undergoing Knee and Hip Replacement,” Clinical and LaboratoryHaematology, Vol. 28, No. 6, 2006, pp. 370-375. doi:10.1111/j.1365-2257.2006.00821.x
[20] M. Patteril, A. Davey-Quinn, J. Gedney, S. Murdoch andM. Bellamy, “Functional Iron Deficiency, Infection and Systemic Inflammatory Response Syndrome in Criticall Illness,” Anaesthia and Intensive Care, Vol. 29, No. 5, 2001, pp. 473-479.
[21] E. Katodritou, E. Terpos, K. Zervas, M. Speletas, D. Kapetanos, C. Kartsios, E. Verrou, A. Banti, S. Effraimidou and J. Christakis, “Hypochromic Erythrocytes (%): A Reliable Marker for Regognizing Iron-Restricted Erythropoiesis and Predicting Response to Erythropoietin in Anemic Patients with Myeloma and Lymphoma,” Annals of Hematology, Vol. 86, No. 5, 2007, pp. 369-376. doi:10.1007/s00277-007-0258-x
[22] G. Mirescu, L. Garneata, C. Capusa and N. Ursea, “Intravenous Iron Supplementation for the Treatment of Anaemia in Pre-Dialyzed Chronic Renal Failure Patients,” Nephrology Dialysis Transplantation, Vol. 21, No. 1, 2005, pp. 120-124. doi:10.1093/ndt/gfi087
[23] S. Anker, J. Comin Colet, G. Fillipatos, R. Willenheimer, K. Dickstein, R. Drexler, T. Luscher, B. Bart, W. Banasiak, J. Niegowska, B-A. Kirwan, C. Mori, B. von Eisenhart Rothe, S. Pocock, P. Poole-Wilson and P. Ponikowski, “Ferric Carboxymaltose in Patients with Heart Failure and Iron Deficiency,” New England Journal of Medicine, Vol. 361, No. 25, 2009, pp. 2436-2447. doi:10.1056/NEJMoa0908355
[24] D. Bentley and P. Williams, “Parenteral Iron Therapy in the Anaemia of Rheumatoid Arthritis,” Rheumatology and Rehabilitation, Vol. 21, No. 2, 1982, pp. 88-92. doi:10.1093/rheumatology/21.2.88

  
comments powered by Disqus

Copyright © 2018 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.